C
CIN Terminal
Cannabis Investor News
A CanIDeal, Inc. Company
J
Live
Loading market data...
Expand
Symbol Name Exchange Last Change Volume Watch
Home Markets Loading…
CNBS ETF

Amplify US Cannabis ETF

NYSEARCA · CNBS

ETF providing concentrated exposure to US cannabis operators and ancillary businesses.

$28.26
-1.52%
Live Price
Price History 5 Years

Analyst Coverage

Cannabis Investor News in-house rating · cin-analyst-v1.0

Neutral Conviction 3/5
36/100 composite
Fundamentals40
Regulatory55
Market15
Editorial30
Composite · trailing 12 months

Amplify Seymour Cannabis ETF earns a Neutral rating in the Neutral band, with a composite score of 36 and conviction at 3/5. Regulatory exposure is the strongest pillar at 55, supported by a global-jurisdiction posture score of 70 and an enforcement subscore of 80. Fundamentals contribute 40 despite unavailable company-level financial data, while editorial registers 30 on limited coverage. Market performance is the principal constraint at 15, reflecting the weakest contribution across the framework and preventing the regulatory profile from translating into a more constructive rating.

Licensed fundamentals data provide no revenue-growth or margin record for the ETF, leaving the financial condition unknown and limiting evidence for earnings quality, operating leverage, or portfolio-level profitability. Primary regulatory filings show no latest filing date and no recorded events across either the 90-day or 180-day observation windows. That sparse cadence produces a filing-cadence subscore of 25, materially below the jurisdiction and enforcement components, although no enforcement hits support the stronger enforcement assessment. Institutional pricing feeds record zero volume, aligning with the liquidity subscore of 15 and signaling minimal observable trading participation. CIN newsroom coverage records no newsroom hits and no brief hits, leaving both editorial subscores at 30 and offering no coverage-based uplift.

The forward catalyst sits squarely within the regulatory pillar, where the favorable global posture and clean enforcement record already provide the strongest foundation. A new primary regulatory filing or a recorded policy event would improve visibility, validate cadence, and potentially lift the composite without relying on unavailable revenue or margin data. Such activity could also generate CIN newsroom coverage, strengthening the editorial pillar, but the direct rating impact remains most closely tied to regulatory documentation. Market participation remains a secondary confirmation signal because zero recorded volume keeps liquidity at the bottom of the framework. The single most important signal to watch is the appearance of a new primary regulatory filing that raises the cadence assessment.

Scored: 2026-09-19Valid through: 2026-11-03Weights: Fundamentals 35% · Regulatory 25% · Market 25% · Editorial 15%
Loading CIN Rating…
Fundamentals SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
Institutional DetailIR, corporate, and filing data from CIN enrichment
IR & AgencyInvestor relations
Corporate DetailsCompany profile
Headquarters
3333 Warrenville Road Suite 350 Lisle, IL 60532
Phone
(855) 267-3837
CEO
William Belden President Bradley
CFO
Robin Tardy National Sales
Website
Company website
Fundamentals & FinancialsRefreshed nightly from licensed fundamentals data
Beta
0.92
Filings & DisclosuresPrimary sources
Filing portal
SEC EDGAR
See something incorrect or missing?

Help us keep coverage accurate. Submit an update for CIN editorial review.

Submit an update
Complimentary Research
Would you like a deeper analysis on this company?

Request a complimentary, fully customized institutional-quality research report — tailored to your investment thesis.

Request Complimentary Report

Amplify US Cannabis ETF (CNBS): ETF Overview

Amplify US Cannabis ETF is a cannabis-sector exchange-traded fund tracked by Cannabis Investor News. Holdings, top weights, fund flows, and performance metrics are updated alongside live pricing.

ETF providing concentrated exposure to US cannabis operators and ancillary businesses.

Latest price: $28.26 (-1.52%) on NYSEARCA.

Historical Price Data

5-year weekly price history, intraday quotes, and 52-week range for CNBS are maintained by Cannabis Investor News and refreshed throughout the trading day.